ÌÇÐÄ´«Ã½

Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
ÌÇÐÄ´«Ã½

Sex Influences the Safety and Therapeutic Efficacy of Cardiac Nanomedicine Technologies.

ÌÇÐÄ´«Ã½

Sex Influences the Safety and Therapeutic Efficacy of Cardiac Nanomedicine Technologies. Small (Weinheim an der Bergstrasse, Germany) Lin, Z., Jiwani, Z., Serpooshan, V., Aghaverdi, H., Yang, P. C., Aguirre, A., Wu, J. C., Mahmoudi, M. 2023: e2305940

Abstract

Nanomedicine technologies are being developed for the prevention, diagnosis, and treatment of cardiovascular disease (CVD), which is the leading cause of death worldwide. Before delving into the nuances of cardiac nanomedicine, it is essential to comprehend the fundamental sex-specific differences in cardiovascular health. Traditionally, CVDs have been more prevalent in males, but it is increasingly evident that females also face significant risks, albeit with distinct characteristics. Females tend to develop CVDs at a later age, exhibit different clinical symptoms, and often experience worse outcomes compared to males. These differences indicate the need for sex-specific approaches in cardiac nanomedicine. This Perspective discusses the importance of considering sex in the safety and therapeutic efficacy of nanomedicine approaches for the prevention, diagnosis, and treatment of CVD.

View details for

View details for